[Histonet] Re: [IHCRG] Uroplakin vendor

ancillarypath <@t> mac.com ancillarypath <@t> mac.com
Wed Feb 21 10:32:37 CST 2007

There you go..

Good luck with the validation. This is not a very sensitive antibody.  
It's good on the low-grade tumors, where it's not needed.


Hadi Yaziji, M.D., Medical Director
Vitro Molecular Laboratories,
President, Ancillary Pathways
7000 SW 62nd Avenue, Suite Penthouse-C
Miami, FL 33143
Tel 305.740.4440
Fax 786.513.0175

This email message, including any attachments, is for the sole use of  
the intended recipients and may contain privileged information.  Any  
unauthorized review, use, disclosure or distribution is prohibited.   
If you are not the intended recipient, please contact the sender by e- 
mail and destroy all copies of the original message.


(anti-Human and others as indicated)

RDI Division of Fitzgerald Industries Intl  offers a wide line of   
antibodies. Since no one antibody works best for all applications  
(neutralization, blotting, ELISA, etc), we offer many different types  
of antibodies to help solve this problem. Please inquire for other  
applications or types of antibodies not listed below.

Uroplakin II clone AU1 (available as 50ug purified or 5ml Ready To  
Use TCS format)

Mab to Uroplakin III (human/bovine)
Cat#RDI-PRO651108     $345.00/vial  5ml TCS formulation

cat#RDI-PRO610108    $410.00/1vial  $375/vial 10+   50ug  
(lyophilized) with 0.5%BSA & 0.09% NaN3

Clone                                 AU1

Category                            Mouse monoclonal

Immunoglobulin Class        IgG1

Form/Purification               Hybridoma culture supernatant


                                            Asymetric unit membrane  
(AUM) preparation from bovine urinary bladder

Description/Specificity     Mab AU1 reacts specifically with  
uroplakin III present in the superficial cell layer of the  
urothelium. Together with uroplakins UP 1A, UP 1b, and UP II,  
uroplakin III contributes in constituting the asymetrical unti  
membrane of the plaques of urothelial glycoprotein (47kD) and has  
been shown to be a specific marker of terminal urothelial  
differentiation (Wu et al., 1983, 1994).

                                       Antibody AU1 strongly stains  
the urothelial surface membrane in paraffin sections of human renal  
pelvis, ureter, bladder, and uretha. About 60% of human transitional  
cell carcinomas (including metastases) maintain focal (sometimes very  
limited) expression of uroplakin III. Until know, no uroplakin  
staining was found in any non-urothelial carcinoma (Moll et al 1995).  
Uroplakin III may thus serve as a specific urothelial  
differentiaition marker in cases of metastatic carcinomas with  
unclear primary tumor

Antigen Recognized in Species (tested so far)     Human, bovine, rat  
(canine reported)

Application Suitable for

                                           · immunohistochemistry on  
paraffin-embedded tissue (NOT ON FROZEN SECTIONS)

                                           · immunoblotting (Western)

Working Dilution                Ready-to-use for immunohistochemistry  

                                             1:10 for histochemistry   

Incubation Time                   1 h at RT for immunohistochemistry

Storage                                 At 2-8°C

On Feb 21, 2007, at 11:27 AM, Orr, Rebecca wrote:

> Could any of you please send me your vendor for Uroplakin Antibody,
> I’m looking for a mouse monoclonal.
> Our application would be for human tissue, in a clinical lab  
> (research use only would be fine)
> Thanks
> Bec
> Assistant Manager, Anatomic Pathology
> Evanston Northwestern Healthcare
> 847-570-2771
> --~--~---------~--~----~------------~-------~--~----~
> You received this message because you are subscribed to the Google  
> Groups "ihcrg" group.
> To post to this group, send email to ihcrg <@t> googlegroups.com
> To unsubscribe from this group, send email to ihcrg- 
> unsubscribe <@t> googlegroups.com
> For more options, visit this group at http://groups.google.com/ 
> group/ihcrg?hl=en
> -~----------~----~----~----~------~----~------~--~---

More information about the Histonet mailing list